NCT06921928 - Study for AZD4360 in Participants With Advanced Solid Tumours | Biotech Hunter

Enrollment

117

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

December 16, 2027

Conditions

Gastric CancerGastroesophageal Junction CancerBiliary Tract CancerPancreatic Ductal Adenocarcinoma

Interventions

DRUG

AZD4360

Antibody-Drug Conjugate targeting Claudin 18.2 (CLDN18.2)

Trial Locations (15)

12200

NOT_YET_RECRUITING

Research Site, Berlin

60488

NOT_YET_RECRUITING

Research Site, Frankfurt

77030

RECRUITING

Research Site, Houston

90404

RECRUITING

Research Site, Santa Monica

100730

NOT_YET_RECRUITING

Research Site, Beijing

201318

RECRUITING

Research Site, Shanghai

430040

RECRUITING

Research Site, Wuhan

610041

RECRUITING

Research Site, Chengdu

02903

NOT_YET_RECRUITING

Research Site, Providence

01307

NOT_YET_RECRUITING

Research Site, Dresden

104-0045

RECRUITING

Research Site, Chūōku

227-8577

RECRUITING

Research Site, Kashiwa

135-8550

RECRUITING

Research Site, Kōtoku

G12 0YN

NOT_YET_RECRUITING

Research Site, Glasgow

EC1A 7BE

NOT_YET_RECRUITING

Research Site, London